As the French market navigates a period of caution amid escalating tensions in the Middle East and a dip in major indices like the CAC 40, investors are keenly observing how these developments might influence growth opportunities. In this context, companies with high insider ownership often attract attention as they suggest confidence from those most familiar with their operations, potentially offering stability and alignment of interests during uncertain times.
Top 10 Growth Companies With High Insider Ownership In France
Overview: Exclusive Networks SA is a global cybersecurity specialist focusing on digital infrastructure, with a market cap of €2.14 billion.
Operations: The company generates revenue from three main regions: €480 million from APAC, €4.19 billion from EMEA, and €705 million from the Americas.
Insider Ownership: 13.1%
Exclusive Networks, a French cybersecurity firm, is experiencing significant growth with earnings expected to rise 33.5% annually over the next three years, outpacing the French market. Despite a dip in profit margins from 5.5% to 2.7%, its revenue growth forecast of 12.2% remains robust compared to the market average of 5.6%. Recently, Permira and Clayton, Dubilier & Rice proposed taking it private at €24.25 per share—a premium reflecting strong insider ownership and strategic interest in its future potential.
Overview: Lectra SA offers industrial intelligence solutions for the fashion, automotive, and furniture markets across Northern Europe, Southern Europe, the Americas, and the Asia Pacific, with a market cap of €1.08 billion.
Operations: The company's revenue segments are distributed as follows: Americas with €172.65 million and Asia-Pacific with €118.54 million.
Insider Ownership: 19.6%
Lectra, a French technology company, is poised for substantial earnings growth at 29.3% annually over the next three years, surpassing the French market's average. Despite recent removal from the S&P Global BMI Index and a decline in net income to €12.51 million for H1 2024, its revenue grew to €262.29 million year-on-year. The stock trades significantly below its estimated fair value with analysts anticipating a 21.3% price increase, reflecting potential upside amidst strong insider ownership dynamics.
Overview: MedinCell S.A. is a pharmaceutical company based in France that specializes in developing long-acting injectables across various therapeutic areas, with a market cap of €436.31 million.
Operations: The company generates its revenue from the Pharmaceuticals segment, amounting to €11.95 million.
Insider Ownership: 15.8%
MedinCell, a French pharmaceutical company, is set for significant growth with forecasted annual revenue increases of 46.2%, outpacing the French market's average. The company anticipates profitability within three years and trades at a substantial discount to its estimated fair value, with analysts predicting a 46.9% price rise. Recent strategic alliances with AbbVie and Teva highlight its innovative BEPO? technology platform's commercial potential, further supported by high insider ownership stability amidst recent governance restructuring.
Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes.
Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Companies discussed in this article include ENXTPA:EXN ENXTPA:LSS and ENXTPA:MEDCL.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]
